Previous 10 | Next 10 |
home / stock / bayry / bayry news
2023-11-20 07:14:14 ET More on Bayer Breaking Up Bayer? Probably Not! Bayer Aktiengesellschaft 2023 Q3 - Results - Earnings Call Presentation Bayer Aktiengesellschaft (BAYZF) Q3 2023 Earnings Call Transcript EU to extend glyphosate use for 10 more years after...
2023-11-16 13:09:47 ET More on Bayer Breaking Up Bayer? Probably Not! Bayer Aktiengesellschaft 2023 Q3 - Results - Earnings Call Presentation Bayer Aktiengesellschaft (BAYZF) Q3 2023 Earnings Call Transcript Bayer pulling lymphoma drug from US market over fai...
2023-11-16 12:35:07 ET Summary Recursion Pharmaceuticals, Inc. proof-of-concept data, from the phase 2 SYCAMORE study using REC-994 for the treatment of patients with Cerebral Cavernous Malformation, expected in the 2nd half of 2024. Safety and preliminary efficacy data, from the ...
2023-11-14 06:41:42 ET Summary Teck Resources is selling its coal business to Glencore, Nippon Steel and POSCO. Bayer is withdrawing its drug Aliqopa from the US market after a failed study. Boeing is increasing production of Patriot missile sensors to meet rising demand. ...
2023-11-13 17:03:00 ET More on Bayer Breaking Up Bayer? Probably Not! Bayer Aktiengesellschaft 2023 Q3 - Results - Earnings Call Presentation Bayer Aktiengesellschaft (BAYZF) Q3 2023 Earnings Call Transcript Bayer considering breakup but not immediate three-w...
2023-11-10 10:56:34 ET Summary Bayer is reporting rather terrible third quarter results, although currency effects had a huge negative impact on the top line. Additionally, Bayer is currently discussing several options how to proceed with the business – including the possib...
Bayer AG ADR (BAYRY) is expected to report $0.28 for Q3 2023
2023-11-08 10:19:05 ET Bayer Aktiengesellschaft (BAYZF) Q3 2023 Earnings Conference Call November 08, 2023 08:00 AM ET Company Participants Jost Reinhard - Senior Vice President & Head-Investor Relations Bill Anderson - Chief Executive Officer Wolfgang Nickl ...
2023-11-08 07:33:42 ET More on Bayer Bayer: Good Value For Money Bayer: Undervalued With Clear Catalysts Bayer: Still A Strong Buy Despite Lowered Guidance For further details see: Bayer considering breakup but not three-way split, CEO Anderson says
2023-11-08 02:03:18 ET More on Bayer AG Bayer Stock: Good Value For Money Bayer: Undervalued With Clear Catalysts Bayer: Still A Strong Buy Despite Lowered Guidance Bayer slapped with $332M jury verdict in Roundup cancer trial Twist Bioscience inks an...
News, Short Squeeze, Breakout and More Instantly...
Bayer AG ADR Company Name:
BAYRY Stock Symbol:
OTCMKTS Market:
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...